Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
The first oral GLP-1 pill received FDA approval on December 22, 2025 with introductory pricing of $149 per month for the lowest dose
Xue S, Wasserfall CH, Parker M, Brusko TM, McGrail S, McGrail K, et al
Continue reading References Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial Zepbound Package Insert FDA FDA Approves New Medication for Chronic Weight Management Tirzepatide Once Weekly for the Treatment of Obesity Tirzepatide as Compared with Semaglutide for the Treatment of Obesity FDA Approves Lilly's Zepbound (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems More about Zepbound (tirzepatide) Check interactions Compare alternatives Pricing & coupons Reviews (726) Drug images Latest FDA alerts (3) Side effects Dosage information During pregnancy Support group FDA approval history Drug class: GLP-1 Drugs Breastfeeding En espaol Patient resources Other brands Professional resources Other brands Related treatment guides Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Current guidelines from the American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity (IFSO) support consideration in patients with BMI 35 kg/m regardless of comorbidities, or BMI 30-34.9 kg/m with metabolic disease
US$ 23.62
US$ 29.34
US$ 25.20
US$ 24.22
